What is the value of treating schizophrenia?

References

• Murray C. J.L., Evans D. B., Acharya A., Baltussen R. M.P.M. Development of WHO guidelines on generalized cost effectiveness analysis. Health Economics 2000; 9: 235–252
   PubMed Web of Science ®Google Scholar
• Tan Torres Edejer T., Baltussen R., Adam T., et al. Making choices in health: WHO, guide to cost-effectiveness analysis. World Health Organization, Geneva 2003
   Google Scholar
• Drummond M. F., O'Brien B., Stoddart G. L., Torrance G. W. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford 1997
   Google Scholar
• George B., Harris A., Mitchell A. Cost-effectiveness analysis and the consistency of decision-making: evidence from Pharmaceutical Reimbursement in Australia (1991–1996). Pharmacoeconomics 2001; 19: 1103–1109
   PubMed Web of Science ®Google Scholar
• Devlin N., Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004; 13: 437–452
   PubMed Web of Science ®Google Scholar
• Rawlins M. D., Culyer A. J. National Institute for Clinical Excellence and its value judgements. British Medical Journal 2004; 329: 224–227
   PubMed Web of Science ®Google Scholar
• Vos T., Haby M. M., Magnus A., Mihalopoulos C., Andrews G., Carter R. Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Australian and New Zealand Journal of Psychiatry 2005; 39: 701–712
   PubMed Web of Science ®Google Scholar
• Andrews G., Issakidis C., Sanderson K., Corry J., Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. British Journal of Psychiatry 2004; 184: 526–533
   PubMed Web of Science ®Google Scholar
• Andrews G., Sanderson K., Corry J., Issakidis C., Lapsley H. Costeffectiveness of current and optimal treatment for schizophrenia. British Journal of Psychiatry 2003; 183: 427–435
   PubMed Web of Science ®Google Scholar
• Sanderson K., Andrews G., Corry J., Lapsley H. Reducing the burden of affective disorders: is evidence-based health care affordable?. Journal of Affective Disorders 2003; 77: 109–125
   PubMed Web of Science ®Google Scholar
• Issakidis C., Sanderson K., Corry J., Andrews G., Lapsley H. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychological Medicine 2004; 34: 19–35
   PubMed Web of Science ®Google Scholar
• Nord E., Pinto J. L., Richardson J., Menzel P., Ubel P. Incorporating societal concerns for fairness in numerical evaluations of health programmes. Health Economics 1999; 8: 25–39
   PubMed Web of Science ®Google Scholar
• Carr V. J., Neil A. L., Halpin S. A., Holmes S., Lewin T. J. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (psychotic) Disorders Study. Australian and New Zealand Journal of Psychiatry 2003; 37: 31–40
   PubMed Web of Science ®Google Scholar
• Carr V. J., Lewin T. J., Neil A. L., Halpin S. A., Holmes S. Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. British Journal of Psychiatry 2004; 184: 517–525
   PubMed Web of Science ®Google Scholar
• Jablensky A., McGrath J., Herrman H., et al. Psychotic disorders in urban areas: an overview of the methods and findings of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000; 34: 221–236
   PubMed Web of Science ®Google Scholar
• Nord E., Richardson J., Street A., Kuhse H., Singer P. Who cares about cost? Does economic analysis impose or reflect social values?. Centre for Health Program Evaluation, Melbourne 1995, Working Paper 46
   Google Scholar
• Dolan P. The measurement of individual utility and social welfare. Journal of Health Economics 1998; 17: 39–52
   PubMed Web of Science ®Google Scholar
• Nord E. A table of values for cost-effectiveness analysis in health care. Journal of the Norwegian Medical Association 1996; 27: 3246–3249, (text in Norewegian)
   Google Scholar
• Dolan P. Aggregating health state valuations: a reply to Erik Nord’s comment. Journal of Health Services Research and Policy 1997; 2: 203–204
   Google Scholar
• Osterdal L. P. A note on cost-value analysis. Health Economics 2003; 12: 247–250
   PubMed Web of Science ®Google Scholar
• Nord E., Pinto J. L., Richardson J., Menzel P., Ubel P. Comments to ‘A note on cost-value analysis’. Health Economics 2003; 12: 251–253
   Google Scholar
• Johannesson M. Health Economics 2001; 10: 573–577, Should we aggregate relative or absolute changes in QALYs
   Google Scholar
• Nord E. My goodness – and yours: a history, and some possible futures, of DALY meanings and valuation procedures. Summary measures of population health: concepts, ethics, measurement and applications, C. J.L. Murray, J. A. Salomon, C. D. Mathers, A. D. Lopez. World Health Organization, Geneva 2002; 139–146
   Google Scholar
• Essink-Bot M. L., Bonsel G. J. How to derive disability weights. Summary measures of population health: concepts, ethics, measurement and applications, C. J.L. Murray, J. A. Salomon, C. D. Mathers, A. D. Lopez. World Health Organization, Geneva 2002; 449–465
   Google Scholar
• Nord E. The desirability of a condition versus the well being and worth of a person. Health Economics 2001; 10: 579–581
   Google Scholar
• Williams A. Health Economics 2001; 10: 583–585, The ‘fair innings argument’ deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson
   Google Scholar